128 related articles for article (PubMed ID: 38521368)
1. TXB-001, a newly-developed polymer-conjugated anthracycline: Significantly lower adverse effects in animal models of alopecia and hand-foot syndrome.
Hirakata M; Tomikawa E; Sakai C; Uchida M; Okano T; Shimozono R; Kawai M; Itaba S; Munakata L; Suzuki R; Oshida K
Toxicol Appl Pharmacol; 2024 Apr; 485():116912. PubMed ID: 38521368
[TBL] [Abstract][Full Text] [Related]
2. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
[TBL] [Abstract][Full Text] [Related]
3. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
4. Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin.
Hu X; Dong M; Liang X; Liu Z; Li Q
Int J Nanomedicine; 2021; 16():471-480. PubMed ID: 33500617
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
6. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
7. Liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome): a case report.
Ni C; Fang J; Qian H; Xu Q; Shen F
J Int Med Res; 2020 Dec; 48(12):300060520974854. PubMed ID: 33356712
[TBL] [Abstract][Full Text] [Related]
8. A novel animal model of tegafur-induced hand-foot syndrome.
Takano-Mochizuki M; Nakajima K; Ishida T; Ohta E; Moriyama T; Asakura S
Toxicol Appl Pharmacol; 2024 Jun; 487():116977. PubMed ID: 38789014
[TBL] [Abstract][Full Text] [Related]
9. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of regional cooling + oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin.
Nara K; Taguchi A; Yamamoto T; Tsuruga T; Tojima Y; Miyamoto Y; Tanikawa M; Sone K; Mori M; Takada T; Suzuki H; Osuga Y
Support Care Cancer; 2023 Apr; 31(5):283. PubMed ID: 37074471
[TBL] [Abstract][Full Text] [Related]
11. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.
Lotem M; Hubert A; Lyass O; Goldenhersh MA; Ingber A; Peretz T; Gabizon A
Arch Dermatol; 2000 Dec; 136(12):1475-80. PubMed ID: 11115157
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
13. The role of the ATM/Chk/P53 pathway in mediating DNA damage in hand-foot syndrome induced by PLD.
Yang J; Qiao L; Zeng Z; Wang J; Zhu T; Wei J; Wu M; Ye S; Huang X; Ma D; Liu R; Gao Q
Toxicol Lett; 2017 Jan; 265():131-139. PubMed ID: 27923599
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin.
Yokomichi N; Nagasawa T; Coler-Reilly A; Suzuki H; Kubota Y; Yoshioka R; Tozawa A; Suzuki N; Yamaguchi Y
Hum Cell; 2013 Mar; 26(1):8-18. PubMed ID: 23386177
[TBL] [Abstract][Full Text] [Related]
15. Liposomal anthracycline administration and toxicity management: a nursing perspective.
Wood LS
Semin Oncol; 2004 Dec; 31(6 Suppl 13):182-90. PubMed ID: 15717743
[TBL] [Abstract][Full Text] [Related]
16. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
17. Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs.
Bavli Y; Winkler I; Chen BM; Roffler S; Cohen R; Szebeni J; Barenholz Y
J Control Release; 2019 Jul; 306():138-148. PubMed ID: 31176656
[TBL] [Abstract][Full Text] [Related]
18. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
[TBL] [Abstract][Full Text] [Related]
19. Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil
Aldughaim MS; Muthana M; Alsaffar F; Barker MD
Molecules; 2020 Dec; 26(1):. PubMed ID: 33379361
[TBL] [Abstract][Full Text] [Related]
20. High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study.
Zhao Y; Su W; Liang G; Shan X; Ma W; Tang D; Li L; Niu X; Zhao S; Zhang Q; Zhao W
BMC Pharmacol Toxicol; 2021 Oct; 22(1):63. PubMed ID: 34696815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
